文献速递免疫规划传染病防控与疫情报告

尼泊尔引入10价肺炎球菌结合疫苗4年后的效果:一项观察性队列研究

Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
PubMed 文献 · Lancet Glob Health · 2022-01-01

该研究在尼泊尔开展观察性队列研究,评估2015年引入10价肺炎球菌结合疫苗(PCV10)后对儿童肺炎球菌携带和疾病的影响。结果显示,2岁以下临床肺炎病例中疫苗血清型携带到2019年下降82%(aPR 0.18,95%CI 0.07-0.50),6-23月龄健康儿童下降75%(aPR 0.25,95%CI 0.19-0.33),但24-59月龄未见下降;PCV13额外血清型携带升高至2.2倍(aPR 2.17,95%CI 1.16-4.05)。

要点

  • 2岁以下肺炎病例疫苗血清型携带下降82%,6-23月龄健康儿童下降75%。
  • 24-59月龄儿童疫苗血清型携带未见下降(aPR 0.59,95%CI 0.29-1.19)。
  • PCV13额外血清型携带升高2.2倍,源于19A和3型增加。

核心结论

  • 尼泊尔将PCV10纳入常规免疫规划减少了健康儿童和2岁以下肺炎患儿的疫苗血清型携带。
  • 19A和3型血清型增加凸显持续监测疫苗规划效果的重要性。
  • 该分析展示了在无法开展肺炎球菌疾病终点有效性研究的情况下评估疫苗效果的稳健方法。

研究设计与样本

  • 观察性队列研究,医院监测在加德满都Patan医院开展,社区研究在加德满都及Okhaldhunga地区开展。
  • 监测研究纳入2014年3月20日至2019年12月31日期间Patan医院收治的2月龄至14岁临床疑似肺炎儿童,共2051例。
  • 社区研究招募健康儿童共11354名(6-23月龄8483名、24-59月龄761名、0-8周龄2110名)评估鼻咽部携带。
  • 评估疫苗引入前1.5年至引入后4.5年的规划效果,肺炎结局采用对数二项模型计算调整患病率比(aPR),调整日历月、年龄和性别。

主要发现

  • 2岁以下临床肺炎病例中疫苗血清型携带到2019年下降82%(aPR 0.18,95%CI 0.07-0.50)。
  • 未接种疫苗的年长年龄组病例中疫苗血清型携带未见下降。
  • PCV13额外血清型携带到2019年升高至2.2倍(aPR 2.17,95%CI 1.16-4.05),源于19A和3型增加。
  • 6-23月龄健康儿童疫苗血清型携带下降75%(aPR 0.25,95%CI 0.19-0.33),24-59月龄未见下降(aPR 0.59,95%CI 0.29-1.19)。
  • 未免疫的8周龄以下儿童疫苗血清型总携带到2019年下降61%(aPR 0.39,95%CI 0.18-0.85);6-23月龄儿童中PCV13额外血清型3和19A在PCV10引入后增加,6A未增加。

临床怎么用

  • 作者认为,19A和3型血清型增加凸显持续监测疫苗规划效果的重要性。
  • 作者指出,该分析展示了在无法开展肺炎球菌疾病终点有效性研究的情况下评估疫苗效果的稳健方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Nepal, Streptococcus pneumoniae (pneumococcus) is a common cause of bacterial pneumonia in children, and is a major health concern. There are few data on the effect of vaccination on the disease or colonisation with pneumococci in the nasopharynx of children in this setting. The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced into the routine infant immunisation schedule in Nepal in 2015. We aimed to investigate the effect of the introduction of PCV10 on pneumococcal carriage and disease in children in Nepal. METHODS: We did an observational cohort study in children in Nepal. The hospital surveillance study took place in Patan Hospital, Kathmandu, and community studies in healthy children took place in Kathmandu and Okhaldhunga district. For the surveillance study, all children admitted to Patan Hospital between March 20, 2014, and Dec 31, 2019, aged between 2 months and 14 years with clinician-suspected pneumonia, were eligible for enrolment. For the community study, healthy children aged 0-8 weeks, 6-23 months, and 24-59 months were recruited from Kathmandu, and healthy children aged 6-23 months were recruited from Okhaldhunga. We assessed the programmatic effect of PCV10 introduction using surveillance for nasopharyngeal colonisation, pneumonia, and invasive bacterial disease from 1·5 years before vaccine introduction and 4·5 years after vaccine introduction. For the surveillance study, nasopharyngeal swabs, blood cultures, and chest radiographs were obtained from children admitted to Patan Hospital with suspected pneumonia or invasive bacterial disease. For the community study, nasopharyngeal swabs were obtained from healthy children in the urban and rural settings. Pneumonia outcomes were analysed using log-binomial models and adjusted prevalence ratios (aPR) comparing each calendar year after the introduction of the vaccine into the national programme with the pre-vaccine period (2014-15), adjusted for calendar month, age, and sex. FINDINGS: Between March 20, 2014, and Dec 31, 2019, we enrolled 2051 children with suspected pneumonia, and 11 354 healthy children (8483 children aged 6-23 months, 761 aged 24-59 months, and 2110 aged 0-8 weeks) to assess nasopharyngeal colonisation. Among clinical pneumonia cases younger than 2 years, vaccine serotype carriage declined 82% (aPR 0·18 [95% CI 0·07-0·50]) by 2019. There was no decrease in vaccine serotype carriage in cases among older unvaccinated age groups. Carriage of the additional serotypes in PCV13 was 2·2 times higher by 2019 (aPR 2·17 [95% CI 1·16-4·05]), due to increases in serotypes 19A and 3. Vaccine serotype carriage in healthy children declined by 75% in those aged 6-23 months (aPR 0·25 [95% CI 0·19-0·33]) but not in those aged 24-59 months (aPR 0·59 [0·29-1·19]). A decrease in overall vaccine serotype carriage of 61% by 2019 (aPR 0·39 [95% CI 0·18-0·85]) was also observed in children younger than 8 weeks who were not yet immunised. Carriage of the additional PCV13 serotypes in children aged 6-23 months increased after PCV10 introduction for serotype 3 and 19A, but not for serotype 6A. The proportion of clinical pneumonia cases with endpoint consolidation on chest radiographs declined from 41% in the pre-vaccine period to 25% by 2018, but rose again in 2019 to 36%. INTERPRETATION: The introduction of the PCV10 vaccine into the routine immunisation programme in Nepal has reduced vaccine serotype carriage in both healthy children and children younger than 2 years with pneumonia. Increases in serotypes 19A and 3 highlight the importance of continued surveillance to monitor the effect of vaccine programmes. This analysis demonstrates a robust approach to assessing vaccine effect in situations in which pneumococcal disease endpoint effectiveness studies are not possible. FUNDING: Gavi, the Vaccine Alliance and the World Health Organization.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Shrestha S, Gurung M, Amatya P, et al. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study. Lancet Glob Health. 2022. PMID: 36113533. doi:10.1016/S2214-109X(22)00281-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。